Colon Cancer
Research activity in colon cancer centers on stage III and high-risk stage II disease, with attention to operable locoregional cases and post-surgical management.
- Post-surgical risk stratification
- Liquid biopsy
- ctDNA-guided treatment
The studies focus on identifying residual disease after surgery and guiding adjuvant treatment decisions through circulating tumor DNA and blood-based molecular markers.
Metastatic Colorectal Cancer
In metastatic colorectal cancer, the sponsor is involved in research for patients with MMR-proficient and extended RAS-mutated tumors, particularly after standard therapies have failed.
- Immunotherapy
- RAS-mutated disease
- MMR-proficient tumors
Key interests include treatment approaches for resistant disease and the use of molecular features to inform targeted oncology strategies.
Advanced Triple Negative Breast Cancer
Work in advanced triple negative breast cancer addresses relapse after curative-intent therapy and explores treatment options for aggressive, difficult-to-treat disease.
- Immune checkpoint therapy
- DNA damage response
- Taxane-based therapy
The research landscape includes interest in restoring sensitivity to immunotherapy and combining molecularly directed approaches with systemic treatment in recurrent disease.
Molecular and Blood-Based Oncology
Across its trials, the sponsor shows strong involvement in molecular oncology, with emphasis on tumor profiling, blood-based biomarkers, and genomic characterization of cancer.
- ctDNA monitoring
- Genomic-based treatment selection
- Biomarker-driven management
These interests connect precision oncology with post-operative surveillance and treatment selection in gastrointestinal and breast cancer settings.
